Resverlogix Corp. has announced that it has received confirmation that its European patent application covering RVX-208 has been granted. European Patent no. 2118074 is titled "Compounds for the prevention and treatment of cardiovascular diseases." The patent life will extend to February 2027.
"We are delighted to have confirmation of this news," stated Don McCaffrey, President and CEO of Resverlogix. "This additional patent builds upon the growing patent estate for RVX-208, our core asset. With a patent life out to 2027, RVX-208 now has critical protection for the next 13 years in the important European marketplace" McCaffrey added.
In addition, Resverlogix has also filed for a fixed dose combination patent, with Rosuvastatin, that if granted will extend the patent life to 2033.
Resverlogix also announced that it entered into a Waiver Agreement with RVX Therapeutics Inc., a wholly-owned subsidiary of Zenith Epigenetics Corp., whereby Resverlogix agreed to waive its right under a License Agreement dated June 3, 2013 to license any method or pharmaceutical agent within the scope of certain Licensee Patents owned or controlled by RVX Therapeutics that may be determined to come within the ApoA-I Therapeutic Field (as defined in the License Agreement), and RVX Therapeutics agreed not to develop any patents and/or compounds for any indication within the ApoA-I Therapeutic Field for a period of five years.
RVX Therapeutics agreed to pay Resverlogix $2.5 million in cash and granted to Resverlogix a right of first refusal for a period of three years thereafter in respect of the license or sale of such patents and/or compounds that are determined to come within the ApoA-I Therapeutic Field.
Entering into the Waiver Agreement generated cash for Resverlogix without impacting on its core assets.
In unrelated news, the Company also announced that a March publication in Cell Metabolism titled "High Density Lipoproteins and Cerebrovascular Integrity in Alzheimer's Disease" includes discussion of RVX-208, Resverlogix's small molecule ApoA-I modulator, as a potential therapeutic for Alzheimer's Disease (AD) (Stukas et al., 2014 Cell Metabolism 19: 1-18).
Prior exploratory clinical data on the effect of RVX-208 on plasma amyloid beta levels, performed from the Phase Ia and Phase II ASSERT studies, is discussed. As these earlier cardiovascular trials were not specifically designed to study Alzheimer's disease, efforts are being undertaken to advance an exploratory trial in an AD patient population.
The Company is planning a Phase II Clinical Trial for the Exploratory Assessment of Alzheimer's Disease following Treatment with RVX-208 in Patients with Alzheimer's and Alzheimer's-like Dementia of Possible Vascular Origin. The trial will target mild to moderate Alzheimer's disease patients.
Additionally, Resverlogix has restructured its clinical CVD program, which will now be formally directed by Dr. Jan Johansson. The Company would like to thank Dr. Allan Gordon for his years of service, and wishes him great success in his future endeavors.